NasdaqGS - Nasdaq Real Time Price USD

Immunovant, Inc. (IMVT)

14.70

+0.24

+(1.66%)

At close: May 19 at 4:00:01 PM EDT

14.70

0.00

(0.00%)

After hours: May 19 at 4:02:06 PM EDT

Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back?

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks that will bounce back. Major US indexes finished in the green on Wednesday, May 7, after a volatile session […]

Insider Monkey 10 days ago

IMVT
+1.66%
Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug

Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets.

Investor's Business Daily 28 days ago

ROIV

IMVT
+1.66%
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-cla

GlobeNewswire 28 days ago

IMVT
+1.66%
Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?

We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against other best low cost stocks to buy according to billionaires. Markets are wobbling, and panic is becoming the headline. At times when […]

Insider Monkey last month

IMVT
+1.66%
Immunovant price target raised to $61 from $58 at Stifel

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab Myasthtenia Gravis and chronic inflammatory demyelinating polyneuropathy studies. The firm believes both studies support its thesis that IMVT-1402 is a highly-derisked asset within the growing/strategically-important fragment crystallizable receptor space. Bottom line, Stifel added that it updated its Immunova

TipRanks last month

IMVT
+1.66%
Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was encouraged to see the impressive absolute improvements in MG-Activities of Daily Living, the firm acknowledges that the placebo-adjusted readout was mid-pack among FcRn inhibitors-better than nipocalimab but below argenx’s (ARGX) Vyvgart and UCB’s (UCBY) Rystiggo, the analyst tells investors. The compan

TipRanks last month

IMVT
+1.66%
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.

Zacks last month

IMVT
+1.66%
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

Investor's Business Daily last month

ROIV

IMVT
+1.66%
Immunovant will not seek approval for MG therapy, despite hitting endpoints

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over the trial’s batoclimab.

Clinical Trials Arena last month

IMVT
+1.66%

GLDAF
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Wednesday, Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase 2b study in chronic inflammatory demyelinating polyneuropathy (CIDP). Immunovant is a member of the Roivant Sciences Ltd. (NASDAQ:ROIV) family of companies. In the Phase 3 MG study, batoclimab met its primary endpoint of mean change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylchol

Benzinga last month

IMVT
+1.66%
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an

GlobeNewswire last month

IMVT
+1.66%
Immunovant claims study success for immune disease drug but holds off on submission

The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.

BioPharma Dive last month

IMVT
+1.66%
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Exec

GlobeNewswire 2 months ago

IMVT
+1.66%
Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 2 months ago

INCY

IMVT
+1.66%

^GSPC
Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently

We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks. We previously covered 10 stocks with at least $20 million in insider spending recently. Trump administration’s tariffs on […]

Insider Monkey 2 months ago

IMVT
+1.66%
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.

Investor's Business Daily 2 months ago

ARGNF

ARGX

BHVN
Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field, Head of European Pharma Research at Barclays, […]

Insider Monkey 2 months ago

IMVT
+1.66%
Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other oversold healthcare stocks. Are Healthcare Costs Rising in the US? Healthcare costs and spending have been rising in the US. The […]

Insider Monkey 2 months ago

IMVT
+1.66%
Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently

We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year, we thought it would be […]

Insider Monkey 2 months ago

IMVT
+1.66%
Roivant Sciences price target lowered to $12 from $13 at BofA

BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call was “relatively uneventful” besides an announcement for initiating a Phase 2 trial for brepocitinib in cutaneous sarcoidosis, the analyst tells investors. The firm continues like the opportunity sets for IMVT-1402, but sees the rest of Roivant’s (ROIV) pipeline as relatively early, says the analyst, who views Roivant and Immunovant (IMVT) as “tightly linked

TipRanks 3 months ago

ROIV

IMVT
+1.66%

Performance Overview

Return	IMVT	S&P 500 (^GSPC)
YTD	-40.65%	+1.39%
1-Year	-52.12%	+12.45%
3-Year	+306.08%	+52.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immunovant, Inc. (IMVT)

Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back?

Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?

Immunovant price target raised to $61 from $58 at Stifel

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.

Immunovant will not seek approval for MG therapy, despite hitting endpoints

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant claims study success for immune disease drug but holds off on submission

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?

Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts

Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently

Roivant Sciences price target lowered to $12 from $13 at BofA

Performance Overview